<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7418</journal-id>
<journal-title><![CDATA[Revista Colombiana de Ciencias Químico - Farmacéuticas]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colomb. cienc. quim. farm.]]></abbrev-journal-title>
<issn>0034-7418</issn>
<publisher>
<publisher-name><![CDATA[Departamento de Farmácia, Facultad de Ciencias, Universidade Nacional da Colombia]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-74182020000200452</article-id>
<article-id pub-id-type="doi">10.15446/rcciquifa.v49n2.89898</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[EGFR and HER2 small molecules inhibitors as potential therapeutics in veterinary oncology]]></article-title>
<article-title xml:lang="es"><![CDATA[Inhibidores EGFR y HER2 como tratamientos potenciales en oncología veterinaria]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cadena García]]></surname>
<given-names><![CDATA[Juan Martín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Giraldo Murillo]]></surname>
<given-names><![CDATA[Carlos Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos Jaramillo]]></surname>
<given-names><![CDATA[Manuela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Caldas Facultad de Ciencias Agropecuarias ]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad de Santa Rosa de Cabal (UNISARC) Facultad de Ciencias Agropecuarias ]]></institution>
<addr-line><![CDATA[Santa Rosa de Cabal ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Caldas Facultad de Ciencias Exactas y Naturales ]]></institution>
<addr-line><![CDATA[Manizales ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2020</year>
</pub-date>
<volume>49</volume>
<numero>2</numero>
<fpage>452</fpage>
<lpage>471</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0034-74182020000200452&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0034-74182020000200452&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0034-74182020000200452&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY EGFR and HER2 receptors are crucial signaling molecules tyrosine kinase involved in human cancer. Aberrant signaling is associated with a variety of cancers, frequently with poor prognosis. Currently, EGFR and HER2 receptors are being targeted by small molecules, which offer a huge benefit to those patients afflicted by aggressive forms of cancer, improving their prognosis. Both human and canine cancers share molecular, biological, histopathological, and clinical similarities, including EGFR and HER2 expression in some forms of cancer. However, despite the use of one tyrosine kinase inhibitor approved to treat canine mastocytoma, canine cancers overexpressed EGFR and HER2 do not yet have targeted therapy, leading to high morbidity and mortality. Targeting EGFR and HER2 receptors in canine cancers using comparative approaches in human cancer could lead to better outcomes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El receptor de factor de crecimiento epidérmico (Epidermal growth factor receptor, EGFR) y el receptor 2 del factor de crecimiento epidérmico (HER2 epidermal growth factor receptor 2) son moléculas señalizadoras cruciales pertenecientes a la familia de proteínas tirosina quinasa involucradas en el cáncer en humanos. La señalización aberrante de dichos receptores se encuentra asociada con una variedad de tumores, frecuentemente asociados a mal pronóstico. Actualmente, EGFR y HER2 son tratados específicamente a través de pequeñas moléculas inhibidoras, las cuales ofrecen un gran beneficio a aquellos pacientes que padecen formas agresivas de cáncer, y de esta manera su pronóstico mejora. Tanto el cáncer en medicina humana como veterinaria comparte similitudes moleculares, biológicas, histopatológicas y clínicas, las cuales incluyen la expresión tanto de EGFR y HER2 en algunas formas de cáncer. Sin embrago, a pesar del uso de un inhibidor tirosina quinasa aprobado para el manejo del mastocitoma canino los tumores que se caracterizan por la sobre-expresión de EGFR y HER2 aún no cuentan con un inhibidor específico, lo cual conduce a alta morbilidad y mortalidad.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Human cancer]]></kwd>
<kwd lng="en"><![CDATA[veterinary cancer]]></kwd>
<kwd lng="en"><![CDATA[EGFR]]></kwd>
<kwd lng="en"><![CDATA[HER2]]></kwd>
<kwd lng="en"><![CDATA[inhibitors]]></kwd>
<kwd lng="es"><![CDATA[Cáncer humano]]></kwd>
<kwd lng="es"><![CDATA[cáncer en veterinaria]]></kwd>
<kwd lng="es"><![CDATA[EGFR]]></kwd>
<kwd lng="es"><![CDATA[HER2]]></kwd>
<kwd lng="es"><![CDATA[inhibidores]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adams]]></surname>
<given-names><![CDATA[VJ.]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[K.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sampson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[J.L.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methods and mortality results of a health survey of purebred dogs in the UK]]></article-title>
<source><![CDATA[J. Small Anim. Pract]]></source>
<year>2010</year>
<volume>51</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>512-24</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Creevy]]></surname>
<given-names><![CDATA[K.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality in North American dogs from 1984 to 2004: An investigation into age-, size-, and breed-related causes of death]]></article-title>
<source><![CDATA[J. Vet. Intern. Med]]></source>
<year>2011</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>187-98</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Egenvall]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Nødtvedt]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hággström]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ström-Holst]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Möller]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bonnett]]></surname>
<given-names><![CDATA[B.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality of life-insured Swedish cats during 1999 -2006: Age, breed, sex, and diagnosis]]></article-title>
<source><![CDATA[J. Vet. Intern. Med]]></source>
<year>2009</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1175-83</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blume-Jensen]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Hunter]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncogenic kinase signalling]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2001</year>
<volume>411</volume>
<page-range>355-65</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergkvist]]></surname>
<given-names><![CDATA[G.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Yool]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor as a therapeutic target in veterinary oncology]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2011</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-94</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mcdowell]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2017</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>890-909</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakai]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Maeda]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Saeki]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-tumour effect oflapatinib in canine transitional cell carcinoma cell lines]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2018</year>
<volume>16</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>642-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. Roskoski]]></surname>
<given-names><![CDATA[Jr.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ErbB/HER family of protein-tyrosine kinases and cancer]]></article-title>
<source><![CDATA[Pharmacol. Res]]></source>
<year>2014</year>
<volume>79</volume>
<page-range>34-74</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lemmon]]></surname>
<given-names><![CDATA[M.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schlessinger]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cell signaling by receptor tyrosine kinases]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2010</year>
<volume>141</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1117-34</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Citri]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Yarden]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EGF - ERBB signalling : towards the systems level]]></article-title>
<source><![CDATA[Nat. Rev. Mol. Cell Biol]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>505-16</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Littlefield]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Mysore]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Shan]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Shaw]]></surname>
<given-names><![CDATA[D.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Jura]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural analysis of the EGFR /HER3 heterodimer reveals the molecular basis for activating HER3 mutations]]></article-title>
<source><![CDATA[Sci. Signal]]></source>
<year>2014</year>
<volume>7</volume>
<numero>354</numero>
<issue>354</issue>
<page-range>ra114</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bergkvist]]></surname>
<given-names><![CDATA[G.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Yool]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor as a therapeutic target in veterinary oncology]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2011</year>
<volume>9</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-94</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hynes]]></surname>
<given-names><![CDATA[N.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[H.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ERBB receptors and cancer: the complexity of targeted inhibitors]]></article-title>
<source><![CDATA[Nat. Rev. Cancer]]></source>
<year>2005</year>
<volume>5</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>341-54</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moy]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kar]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Goss]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lapatinib]]></article-title>
<source><![CDATA[Nat. Rev. Drug Discov]]></source>
<year>2007</year>
<volume>6</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>431-2</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nahta]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Hortobagyi]]></surname>
<given-names><![CDATA[G.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Esteva]]></surname>
<given-names><![CDATA[F.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Growth factor receptors in breast cancer: potential for therapeutic intervention]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2003</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-17</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aertgeerts]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Skene]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Yano]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein]]></article-title>
<source><![CDATA[J. Biol. Chem]]></source>
<year>2011</year>
<volume>286</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>18756-65</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tzahar]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Waterman]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor]]></article-title>
<source><![CDATA[Mol. Cell. Biol]]></source>
<year>1996</year>
<volume>16</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>5276-87</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. Roskoski]]></surname>
<given-names><![CDATA[Jr.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The ErbB/HER receptor protein-tyrosine kinases and cancer]]></article-title>
<source><![CDATA[Biochem. Biophys. Res. Commun]]></source>
<year>2004</year>
<volume>319</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. Ghosh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Narasanna]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2011</year>
<volume>71</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1871-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yarden]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Sliwkowski]]></surname>
<given-names><![CDATA[M.X.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Untangling the ErbB signalling network]]></article-title>
<source><![CDATA[Nat. Rev. Mol. Cell. Biol]]></source>
<year>2001</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>127-37</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[R.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Gordus]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Krall]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Macbeath]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A quantitative protein interaction network for the ErbB receptors using protein microarrays]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2006</year>
<volume>439</volume>
<page-range>168-74</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lenferink]]></surname>
<given-names><![CDATA[A.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Pinkas-Kramarski]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[van de Poll]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers]]></article-title>
<source><![CDATA[EMBO J]]></source>
<year>1998</year>
<volume>17</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>3385-97</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baulida]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kraus]]></surname>
<given-names><![CDATA[M.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Alimandi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Paolo]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Fiore]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Carpenter]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired (*)]]></article-title>
<source><![CDATA[J. Biol. Chem]]></source>
<year>1996</year>
<volume>271</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>5251-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinkas-kramarski]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Soussan]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Waterman]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions]]></article-title>
<source><![CDATA[EMBO J]]></source>
<year>1996</year>
<volume>15</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2452-67</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lurje]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Lenz]]></surname>
<given-names><![CDATA[H.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EGFR signaling and drug discovery]]></article-title>
<source><![CDATA[Oncology]]></source>
<year>2009</year>
<volume>77</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>400410</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowman]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Turkson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Jove]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[STATs in oncogenesis]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2000</year>
<volume>19</volume>
<numero>21</numero>
<issue>21</issue>
<page-range>2474-88</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Soltoff]]></surname>
<given-names><![CDATA[S.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Cantley]]></surname>
<given-names><![CDATA[L.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[p120cbl is a cytosolic adapter protein that associates with phosphoinositide 3-kinase in response to epidermal growth factor in PC12 and other cells]]></article-title>
<source><![CDATA[J. Biol. Chem]]></source>
<year>1996</year>
<volume>271</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>563-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zandi]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Larsen]]></surname>
<given-names><![CDATA[A.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Andersen]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Stockhausen]]></surname>
<given-names><![CDATA[M.T.]]></given-names>
</name>
<name>
<surname><![CDATA[Poulsen]]></surname>
<given-names><![CDATA[H.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms for oncogenic activation of the epidermal growth factor receptor]]></article-title>
<source><![CDATA[Cell Signal]]></source>
<year>2007</year>
<volume>19</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2013-23</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Niu]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[K.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2002</year>
<volume>21</volume>
<page-range>2000-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanahan]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hallmarks of cancer: The next generation]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2011</year>
<volume>144</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>646-74</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ménard]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Pupa]]></surname>
<given-names><![CDATA[S.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Campiglio]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Tagliabue]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Biologic and therapeutic role of HER2 in cancer]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2003</year>
<volume>22</volume>
<numero>42</numero>
<issue>42</issue>
<page-range>6570-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanahan]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Weinberg]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The hallmarks of cancer]]></article-title>
<source><![CDATA[Cell]]></source>
<year>2000</year>
<volume>100</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-70</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sorkin]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Goh]]></surname>
<given-names><![CDATA[L.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocytosis and intracellular trafficking of ErbBs]]></article-title>
<source><![CDATA[Exp. Cell. Res]]></source>
<year>2009</year>
<volume>315</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>683-96</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Levkowitz]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Waterman]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Zamir]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination o the epidermal growth factor receptor]]></article-title>
<source><![CDATA[Genes Dev]]></source>
<year>1998</year>
<volume>12</volume>
<page-range>3663-74</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Harrington]]></surname>
<given-names><![CDATA[K.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Rhys-Evans]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[O-Charoenrat]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[S.A. Eccles, Biological significance of c-erbB family oncogenes in head and neck cancer]]></article-title>
<source><![CDATA[Cancer Metastasis Rev]]></source>
<year>2005</year>
<volume>24</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>47-69</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[S.V.]]></given-names>
</name>
<name>
<surname><![CDATA[Bell]]></surname>
<given-names><![CDATA[D.W.]]></given-names>
</name>
<name>
<surname><![CDATA[Settleman]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Haber]]></surname>
<given-names><![CDATA[D.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor mutations in lung cancer]]></article-title>
<source><![CDATA[Nat. Rev. Cancer]]></source>
<year>2007</year>
<volume>7</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>169-81</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mrhalova]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Plzak]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Betka]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kodet]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor - its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas]]></article-title>
<source><![CDATA[Neoplasma]]></source>
<year>2005</year>
<volume>52</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>338-43</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[Cordell]]></surname>
<given-names><![CDATA[K.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking]]></article-title>
<source><![CDATA[Int. J. Radiat. Oncol. Biol. Phys]]></source>
<year>2007</year>
<volume>69</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>109-11</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grandis]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Tweardy]]></surname>
<given-names><![CDATA[D.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1993</year>
<volume>53</volume>
<page-range>3579-84</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sibilia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Kroismayr]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Lichtenberger]]></surname>
<given-names><![CDATA[B.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Natarajan]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hecking]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Holcmann]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The epidermal growth factor receptor: from development to tumorigenesis]]></article-title>
<source><![CDATA[Differentiation]]></source>
<year>2007</year>
<volume>75</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>770-87</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Terragni]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Gardini]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Sabattini]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EGFR, HER-2 and KRAS in canine gastric epithelial tumors: A potential human model?]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Higgins]]></surname>
<given-names><![CDATA[R.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Dickinson]]></surname>
<given-names><![CDATA[P.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lecouteur]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Spontaneous canine gliomas: Overexpression of EGFR, PDGFRa and IGFBP2 demonstrated by tissue micro-array immunophenotyping]]></article-title>
<source><![CDATA[J. Neurooncol]]></source>
<year>2010</year>
<volume>98</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>49-55</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Duke]]></surname>
<given-names><![CDATA[S.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H.J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA["Putting our heads together": Insights into genomic conservation between human and canine intracranial tumors]]></article-title>
<source><![CDATA[J. Neurooncol]]></source>
<year>2009</year>
<volume>94</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-49</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[H.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[A.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Luwor]]></surname>
<given-names><![CDATA[R.B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EGFRvIII variant in glioblastoma multiforme]]></article-title>
<source><![CDATA[J. Clin. Neurosci.]]></source>
<year>2009</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>748-54</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baselga]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Why the epidermal growth factor receptor? The rationale for cancer therapy]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2002</year>
<volume>7</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
<page-range>2-8</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milas]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[K.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Ang]]></surname>
<given-names><![CDATA[K.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor and its inhibition in radiotherapy: In vivo findings]]></article-title>
<source><![CDATA[Int. J. Radiat. Biol]]></source>
<year>2003</year>
<volume>79</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>539-54</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwaederle]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Arguello]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HER2 expression status in diverse cancers : review of results]]></article-title>
<source><![CDATA[Cancer Metastasis Rev]]></source>
<year>2015</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>157-64</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[M.D.]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[D.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Kies]]></surname>
<given-names><![CDATA[M.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Mao]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Weber]]></surname>
<given-names><![CDATA[R.S.]]></given-names>
</name>
<name>
<surname><![CDATA[El-Naggar]]></surname>
<given-names><![CDATA[A.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: Empirical and therapeutic significance]]></article-title>
<source><![CDATA[Clin. Cancer Res]]></source>
<year>2010</year>
<volume>16</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2266-74</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[B.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Kurzrock]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HER2 aberrations in cancer: Implications for therapy]]></article-title>
<source><![CDATA[Cancer Treat. Rev]]></source>
<year>2014</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>770-80</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cappuzzo]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Bemis]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Varella-Garcia]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer]]></article-title>
<source><![CDATA[N. Engl. J. Med]]></source>
<year>2006</year>
<volume>354</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>2619-21</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Randall]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Brothman]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Maxwell]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Coffin]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Goldsby]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification]]></article-title>
<source><![CDATA[J. Pediatr. Hematol. Oncol]]></source>
<year>2003</year>
<volume>25</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>27-32</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mason]]></surname>
<given-names><![CDATA[N.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Gnanandarajah]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Engiles]]></surname>
<given-names><![CDATA[J.B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2016</year>
<volume>22</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>4380-90</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tyrosine kinase inhibitors in veterinary medicine]]></article-title>
<source><![CDATA[Top. Companion Anim. Med]]></source>
<year>2009</year>
<volume>24</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>106-12</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klopfleisch]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Klose]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Gruber]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The combined expression pattern of BMP2, LTBP4, and DERL1 discriminates malignant from benign canine mammary tumors]]></article-title>
<source><![CDATA[Vet. Pathol]]></source>
<year>2010</year>
<volume>47</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>446-54</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Looper]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Malarkey]]></surname>
<given-names><![CDATA[D.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Ruslander]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Proulx]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Thrall]]></surname>
<given-names><![CDATA[D.E.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidermal growth factor receptor expression in feline oral squamous cell carcinomas]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2006</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-40</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grabarevic]]></surname>
<given-names><![CDATA[Z.]]></given-names>
</name>
<name>
<surname><![CDATA[Coric]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Seiwerth]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative analysis of hepatocellular carcinoma in men and dogs]]></article-title>
<source><![CDATA[Coll. Antropol]]></source>
<year>2009</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>811-4</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stoica]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[H.-T.]]></given-names>
</name>
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[D.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Coates]]></surname>
<given-names><![CDATA[J.R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Morphology, immunohistochemistry, and genetic alterations in dog astrocytomas]]></article-title>
<source><![CDATA[Vet. Pathol]]></source>
<year>2004</year>
<volume>41</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>10-9</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ipsitz]]></surname>
<given-names><![CDATA[D.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Iggins]]></surname>
<given-names><![CDATA[R.J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Ortz]]></surname>
<given-names><![CDATA[G.D.K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glioblastoma multiforme: clinical findings, magnetic resonance imaging , and pathology in five dogs]]></article-title>
<source><![CDATA[Vet. Pathol]]></source>
<year>2003</year>
<volume>40</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>659-69</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[A.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Matos]]></surname>
<given-names><![CDATA[A.J.F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Advances in the understanding of the clinically relevant genetic pathways and molecular aspects of canine mammary tumours. Part 2: Invasion, angiogenesis, metastasis and therapy]]></article-title>
<source><![CDATA[Vet. J.]]></source>
<year>2015</year>
<volume>205</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>144-53</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Guimarães]]></surname>
<given-names><![CDATA[M.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EGFR and microvessel density in canine malignant mammary tumours]]></article-title>
<source><![CDATA[Res. Vet. Sci]]></source>
<year>2013</year>
<volume>95</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1094-9</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gama]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gártner]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunohistochemical expression of Epidermal Growth Factor Receptor (EGFR) in canine mammary tissues]]></article-title>
<source><![CDATA[Res. Vet. Sci]]></source>
<year>2009</year>
<volume>87</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>432-7</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[N.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[H.Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Im]]></surname>
<given-names><![CDATA[K.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[J.H.]]></given-names>
</name>
<name>
<surname><![CDATA[Sur]]></surname>
<given-names><![CDATA[J.-H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of triple-negative and basal-like canine mammary carcinomas using four basal markers]]></article-title>
<source><![CDATA[J. Comp. Pathol]]></source>
<year>2013</year>
<volume>148</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>298-306</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sassi]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Benazzi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Castellani]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Sarli]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry]]></article-title>
<source><![CDATA[BMC Vet. Res]]></source>
<year>2010</year>
<volume>6</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gama]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: Application of the human classification]]></article-title>
<source><![CDATA[VirchowsArch]]></source>
<year>2008</year>
<volume>453</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>123-32</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Queiroga]]></surname>
<given-names><![CDATA[F.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Perez-Alenza]]></surname>
<given-names><![CDATA[M.D.]]></given-names>
</name>
<name>
<surname><![CDATA[González-Gil]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Silván]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Illera]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantification of epidermal growth factor receptor (EGFR) in canine mammary tumours by ELISA assay: Clinical and prognostic implications]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2017</year>
<volume>15</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>383-90</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martín de las Mulas]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Ordás]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Millán]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Soria]]></surname>
<given-names><![CDATA[V.]]></given-names>
</name>
<name>
<surname><![CDATA[Ramón]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Cajal]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oncogene HER-2 in canine mammary gland carcinomas: An immunohistochemical and chromogenic in situ hybridization study]]></article-title>
<source><![CDATA[Breast Cancer Res. Treat]]></source>
<year>2003</year>
<volume>80</volume>
<page-range>363-7</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Millanta]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Impellizeri]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[McSherry]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Rocchigiani]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Aurisicchio]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Lubas]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2018</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>297-300</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Flint]]></surname>
<given-names><![CDATA[A.F.]]></given-names>
</name>
<name>
<surname><![CDATA[U'Ren]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Legare]]></surname>
<given-names><![CDATA[M.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Withrow]]></surname>
<given-names><![CDATA[S.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Dernell]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<name>
<surname><![CDATA[Hanneman]]></surname>
<given-names><![CDATA[W.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overexpression of the erbB-2 proto-oncogene in canine osteosarcoma cell lines and tumors]]></article-title>
<source><![CDATA[Vet. Pathol]]></source>
<year>2004</year>
<volume>41</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>291-6</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murua-Escobar]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
<name>
<surname><![CDATA[Becker]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Bullerdiek]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Nolte]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The canine ERBB2 gene maps to a chromosome region frequently affected by aberrations in tumors of the dog (Canis familiaris)]]></article-title>
<source><![CDATA[Cytogenet. Cell Genet]]></source>
<year>2001</year>
<volume>94</volume>
<numero>3-4</numero>
<issue>3-4</issue>
<page-range>194-5</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[T.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Clausen]]></surname>
<given-names><![CDATA[M.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[FDA-approved small-molecule kinase inhibitors]]></article-title>
<source><![CDATA[Trends Pharmacol. Sci]]></source>
<year>2015</year>
<volume>36</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>422-39</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[R.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Toader]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ferguson]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural approaches to obtain kinase selectivity]]></article-title>
<source><![CDATA[Trends Pharmacol. Sci]]></source>
<year>2012</year>
<volume>33</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>273-8</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Noble]]></surname>
<given-names><![CDATA[M.E.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Endicott]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[L.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Protein kinase inhibitors: insights into drug design from structure]]></article-title>
<source><![CDATA[Science]]></source>
<year>2004</year>
<volume>303</volume>
<numero>5665</numero>
<issue>5665</issue>
<page-range>1800-5</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tevaarwerk]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Kolesar]]></surname>
<given-names><![CDATA[J.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lapatinib: A small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyro-sine kinases used in the treatment of breast cancer]]></article-title>
<source><![CDATA[Clin. Therapeut]]></source>
<year>2009</year>
<volume>31</volume>
<page-range>2332-48</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[E.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Truesdale]]></surname>
<given-names><![CDATA[A.T.]]></given-names>
</name>
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[O.B.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2004</year>
<volume>64</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>6652-9</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Tarrant]]></surname>
<given-names><![CDATA[M.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[S.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of activation and inhibition of the HER4/ErbB4]]></article-title>
<source><![CDATA[kinase, Structure]]></source>
<year>2008</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>460-7</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsou]]></surname>
<given-names><![CDATA[H.-R.]]></given-names>
</name>
<name>
<surname><![CDATA[Overbeek-klumpers]]></surname>
<given-names><![CDATA[E.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Hallett]]></surname>
<given-names><![CDATA[W.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity]]></article-title>
<source><![CDATA[J. Med. Chem]]></source>
<year>2005</year>
<volume>48</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1107-31</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rabindran]]></surname>
<given-names><![CDATA[S.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Discafani]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Rosfjord]]></surname>
<given-names><![CDATA[E.C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2004</year>
<volume>64</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3958-65</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wissner]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Mansour]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The vevelopment of HKI-272 and related compounds for the treatment of cancer]]></article-title>
<source><![CDATA[Arch. Pharm. Chem. Life Sci]]></source>
<year>2008</year>
<volume>341</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>465-77</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tiwari]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Abraham]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Neratinib]]></surname>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[a novel HER2-targeted tyrosine inhibitor]]></article-title>
<source><![CDATA[Clin. Breast Cancer]]></source>
<year>2016</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>344-8</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Solca]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Zoephel]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker]]></article-title>
<source><![CDATA[J. Pharmacol. Exp. Ther]]></source>
<year>2012</year>
<volume>343</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>342-50</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[R. Roskoski]]></surname>
<given-names><![CDATA[Jr.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors]]></article-title>
<source><![CDATA[Pharmacol. Res]]></source>
<year>2014</year>
<volume>87</volume>
<page-range>42-59</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hurvitz]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Shatsky]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Harbeck]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Afatinib in the treatment of breast cancer]]></article-title>
<source><![CDATA[Expert Opin. Investig. Drugs]]></source>
<year>2014</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1039-47</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Ambrogio]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Shimamura]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[BIBW2992, an irreversible EGFR/ HER2 inhibitor highly effective in preclinical lung cancer models]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>4702-11</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y.]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Downregulation of HER3 by a novel anti-sense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models]]></article-title>
<source><![CDATA[Mol. Cancer Iher]]></source>
<year>2013</year>
<volume>12</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>427-37</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Canonici]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Browne]]></surname>
<given-names><![CDATA[B.]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Crown]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donovan]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines]]></article-title>
<source><![CDATA[J Clin. Oncol]]></source>
<year>2013</year>
<volume>31</volume>
<numero>^s15</numero>
<issue>^s15</issue>
<supplement>15</supplement>
<page-range>632</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Godone]]></surname>
<given-names><![CDATA[R.L.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Leitão]]></surname>
<given-names><![CDATA[G.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Araújo]]></surname>
<given-names><![CDATA[N.B.]]></given-names>
</name>
<name>
<surname><![CDATA[Castelletti]]></surname>
<given-names><![CDATA[C.H.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Lima-Filho]]></surname>
<given-names><![CDATA[J.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[D.B.G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and molecular aspects of breast cancer: Targets and therapies]]></article-title>
<source><![CDATA[Biomed. Pharmacother]]></source>
<year>2018</year>
<volume>106</volume>
<page-range>14-34</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Munster]]></surname>
<given-names><![CDATA[P.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[New protein kinase inhibitors in breast cancer: afatinib and neratinib]]></article-title>
<source><![CDATA[Expert Opin. Pharmacother]]></source>
<year>2014</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1277-88</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engelman]]></surname>
<given-names><![CDATA[J.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Zejnullahu]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Gale]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PF00299804, an irreversible Pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2007</year>
<volume>67</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>11924-33</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Hook]]></surname>
<given-names><![CDATA[K.E.]]></given-names>
</name>
<name>
<surname><![CDATA[Althaus]]></surname>
<given-names><![CDATA[I.W.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antitumor activity and pharma-cokinetic properties of PF-00299804 , a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor]]></article-title>
<source><![CDATA[Mol. Cancer Ther]]></source>
<year>2008</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1880-9</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liao]]></surname>
<given-names><![CDATA[B.-C.]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[C.-C.]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J.C.-H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer]]></article-title>
<source><![CDATA[Curr. Opin. Oncol]]></source>
<year>2015</year>
<volume>27</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>94-101</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ramalingam]]></surname>
<given-names><![CDATA[S.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Blackhall]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
<name>
<surname><![CDATA[Krzakowski]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer]]></article-title>
<source><![CDATA[J. Clin. Oncol]]></source>
<year>2012</year>
<volume>30</volume>
<numero>27</numero>
<issue>27</issue>
<page-range>3337-44</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Weichselbaumer]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Stockner]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastu-zumab targeting]]></article-title>
<source><![CDATA[Mol. Immunol]]></source>
<year>2012</year>
<volume>50</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>200-9</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindblad-Toh]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Wade]]></surname>
<given-names><![CDATA[C.M.]]></given-names>
</name>
<name>
<surname><![CDATA[Mikkelsen]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Genome sequence, comparative analysis and haplotype structure of the domestic dog]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2005</year>
<volume>438</volume>
<numero>7069</numero>
<issue>7069</issue>
<page-range>803-19</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoeppner]]></surname>
<given-names><![CDATA[M.P.]]></given-names>
</name>
<name>
<surname><![CDATA[Lundquist]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Pirun]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An improved canine genome and a comprehensive catalogue of coding genes and non-coding transcripts]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2014</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rivera]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[von Euler]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular biological aspects on canine and human mammary tumors]]></article-title>
<source><![CDATA[Vet. Pathol]]></source>
<year>2011</year>
<volume>48</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>132-46</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visan]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Balacescu]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Berindan-Neagoe]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Catoi]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In vitro comparative models for canine and human breast cancer]]></article-title>
<source><![CDATA[ClujulMed]]></source>
<year>2016</year>
<volume>89</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-49</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borge]]></surname>
<given-names><![CDATA[K.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Nord]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Van-Loo]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canine mammary tumours are affected by frequent copy number aberrations, Including amplification of MYC and loss of PTEN]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Queiroga]]></surname>
<given-names><![CDATA[F.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Raposo]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Carvalho]]></surname>
<given-names><![CDATA[M.I.]]></given-names>
</name>
<name>
<surname><![CDATA[Prada]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Pires]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Canine mammary tumours as a model to study human breast cancer: most recent findings]]></article-title>
<source><![CDATA[In Vivo]]></source>
<year>2011</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>455-65</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Hannah]]></surname>
<given-names><![CDATA[A.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Zadovoskaya]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies]]></article-title>
<source><![CDATA[Clin. Cancer Res]]></source>
<year>2003</year>
<volume>9</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2755-68</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papaetis]]></surname>
<given-names><![CDATA[G.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Syrigos]]></surname>
<given-names><![CDATA[K.N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies]]></article-title>
<source><![CDATA[BioDrugs]]></source>
<year>2009</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>377-89</page-range></nlm-citation>
</ref>
<ref id="B101">
<label>101</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Small molecule inhibitors in veterinary oncology practice]]></article-title>
<source><![CDATA[Vet. Clin. North Am., SmallAnim. Pract]]></source>
<year>2014</year>
<volume>44</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>893-908</page-range></nlm-citation>
</ref>
<ref id="B102">
<label>102</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Mathie]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
<name>
<surname><![CDATA[Stingle]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2012</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>194-205</page-range></nlm-citation>
</ref>
<ref id="B103">
<label>103</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marcinowska]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Warland]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Brearley]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Dobson]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A novel approach to treatment oflymphangiosarcoma in a boxer dog]]></article-title>
<source><![CDATA[J. Small Anim. Pract]]></source>
<year>2013</year>
<volume>54</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>334-7</page-range></nlm-citation>
</ref>
<ref id="B104">
<label>104</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chon]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[McCartan]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Kubicek]]></surname>
<given-names><![CDATA[L.N.]]></given-names>
</name>
<name>
<surname><![CDATA[Vail]]></surname>
<given-names><![CDATA[D.M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety evaluation of combination toceranib phosphate (Palladia) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): A phase I dose-finding study]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2012</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>184-93</page-range></nlm-citation>
</ref>
<ref id="B105">
<label>105</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robat]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
<name>
<surname><![CDATA[Bunting]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: A phase I dose-finding study]]></article-title>
<source><![CDATA[Vet. Comp. Oncol]]></source>
<year>2012</year>
<volume>10</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>174-83</page-range></nlm-citation>
</ref>
<ref id="B106">
<label>106</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlsten]]></surname>
<given-names><![CDATA[K.S.]]></given-names>
</name>
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[C.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Haney]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Burnett]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Avery]]></surname>
<given-names><![CDATA[A.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Thamm]]></surname>
<given-names><![CDATA[D.H.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multicenter prospective trial of hypofractionated radiation treatment, tocera-nib, and prednisone for measurable canine mast cell tumors]]></article-title>
<source><![CDATA[J. Vet. Intern. Med]]></source>
<year>2012</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>135-41</page-range></nlm-citation>
</ref>
<ref id="B107">
<label>107</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marconato]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
<name>
<surname><![CDATA[Bettini]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Giacoboni]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological features and outcome for dogs with mast cell tumors and bone marrow involvement]]></article-title>
<source><![CDATA[J. Vet. Intern. Med]]></source>
<year>2008</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1001-7</page-range></nlm-citation>
</ref>
<ref id="B108">
<label>108</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isotani]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Ishida]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Tominaga]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs]]></article-title>
<source><![CDATA[J. Vet. Intern. Med]]></source>
<year>2008</year>
<volume>22</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>985-8</page-range></nlm-citation>
</ref>
<ref id="B109">
<label>109</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yamada]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Sugisaki]]></surname>
<given-names><![CDATA[O.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A&gt;T mutation via suppression of constitutive KIT activation]]></article-title>
<source><![CDATA[Vet. Immunol. Immunopathol]]></source>
<year>2011</year>
<volume>142</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>101-6</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
